Genentech, Inc.'s Levinson May Have No Change-of-Control Agreement in Roche Deal

BNET -- Genentech CEO Arthur Levinson gets no special benefits for agreeing to sell his company to Roche for $95 a share, according to the company’s most recently filed proxy statement.

MORE ON THIS TOPIC